```html

Quasi‑Septal Hypertrophic Cardiomyopathy (QSHCM)

Overview

Quasi‑septal hypertrophic cardiomyopathy (QSHCM) is a relatively rare variant of hypertrophic cardiomyopathy (HCM) in which the thickening of the heart muscle is most pronounced in the basal septal region (the area where the right and left ventricles meet) but does not produce the classic “asymmetric septal hypertrophy” seen in typical HCM. The term “quasi‑septal” reflects that the hypertrophy is mainly, but not exclusively, confined to the septal wall and may extend into adjacent anterior or anterolateral walls.

QSHCM belongs to the spectrum of genetic cardiomyopathies that affect the heart’s ability to pump blood efficiently. Because the condition is often familial, it can appear in otherwise healthy‑looking individuals, including athletes, and may be discovered incidentally on imaging. However, it also carries a risk for arrhythmias, outflow‑tract obstruction, and sudden cardiac death (SCD).

• Who it affects: Both males and females, typically diagnosed between ages 15‑45, though late‑onset cases are reported.
• Prevalence: HCM affects roughly 1 in 500 people worldwide (Mayo Clinic). QSHCM is estimated to represent 5‑10 % of all HCM phenotypes, giving an approximate prevalence of 1‑2 per 10,000 individuals.

Symptoms

Symptoms can range from none (asymptomatic) to severe. The presence and intensity often depend on the degree of septal thickening, obstruction of the left ventricular outflow tract (LVOT), and co‑existing arrhythmias.

Typical symptom list

• Dyspnea (shortness of breath): especially during exertion or when lying flat (orthopnea).
• Exertional chest discomfort or angina: caused by reduced coronary perfusion due to high intraventricular pressure.
• Palpitations: awareness of irregular or rapid heartbeats, often due to atrial fibrillation or ventricular ectopy.
• Syncope or near‑syncope: fainting spells, usually triggered by exertion, dehydration, or sudden posture changes.
• Fatigue: reduced cardiac output can lead to chronic tiredness.
• Exercise intolerance: inability to sustain previous levels of physical activity.
• Heart murmur: a systolic ejection murmur heard best at the left lower sternal border; it may increase with Valsalva or standing.
• Sudden cardiac arrest (SCA): in rare cases, particularly in young athletes; often the first manifestation.
• Peripheral edema: swelling of ankles/feet if left ventricular failure develops.
• Light‑headedness or dizziness: due to low cardiac output or arrhythmias.

Causes and Risk Factors

QSHCM is primarily a genetic disease, but environmental modifiers can influence disease expression.

Genetic Causes

• Sarcomere protein mutations: most commonly in MYH7 (β‑myosin heavy chain) and MYBPC3 (myosin‑binding protein C). These mutations impair contractile function, leading to myocyte hypertrophy.
• Other genes: TNNT2, TCAP, and ACTC1 have been reported in QSHCM phenotypes.
• Inheritance pattern: autosomal‑dominant with variable penetrance; a single pathogenic allele can cause disease, but expression may differ among family members.

Non‑genetic Risk Modifiers

• Intense physical activity: high‑intensity endurance sports may accelerate hypertrophy or provoke arrhythmias in carriers.
• Hypertension: chronic pressure overload can worsen septal thickening.
• Age‑related fibrosis: progressive deposition of fibrotic tissue can increase arrhythmic risk.

Who is at Higher Risk?

• First‑degree relatives of a diagnosed patient.
• People with known pathogenic sarcomere mutations.
• Athletes who experience unexplained exertional symptoms.
• Individuals with a personal or family history of sudden cardiac death.

Diagnosis

Diagnosing QSHCM requires a combination of clinical assessment, imaging, and, when appropriate, genetic testing.

Clinical Evaluation

• Detailed history focusing on exertional symptoms, syncope, family cardiac history, and medication use.
• Physical exam – detection of a systolic murmur, assessment of blood pressure, and evaluation for signs of heart failure.

Imaging and Testing

• Echocardiography (transthoracic echo): first‑line tool; shows septal thickness ≥15 mm (or ≥13 mm with a relative wall thickness >0.5) localized to the basal septum.
• Cardiac Magnetic Resonance (CMR): offers superior tissue characterization; late gadolinium enhancement (LGE) quantifies fibrosis, which predicts arrhythmic risk (JACC 2020).
• Exercise stress testing: evaluates functional capacity and reproduces LVOT gradients.
• 24‑hour Holter or event monitor: screens for atrial fibrillation, non‑sustained ventricular tachycardia (NSVT), and other arrhythmias.
• Genetic testing: panel testing for sarcomere genes; recommended for patients and willing relatives.
• Cardiac catheterization: rarely needed, reserved for invasive gradient measurement or when coronary artery disease is suspected.

Diagnostic Criteria (simplified)

1. Unexplained left ventricular wall thickness ≥15 mm, with a predominance in the basal septum.
2. Absence of other causes of hypertrophy (e.g., hypertension, aortic stenosis, infiltrative disease).
3. Supportive findings: LVOT gradient ≥30 mmHg at rest or with provocation, positive family history, or pathogenic sarcomere mutation.

Treatment Options

Treatment aims to relieve symptoms, prevent obstruction, reduce arrhythmic risk, and improve quality of life.

Medications

• Beta‑blockers (e.g., metoprolol, atenolol): first‑line for symptom control; lower heart rate and reduce LVOT gradient.
• Non‑dihydropyridine calcium channel blockers (e.g., verapamil, diltiazem): useful if beta‑blockers are contraindicated or insufficient.
• Disopyramide: a class Ia anti‑arrhythmic with negative inotropic effect; often combined with beta‑blockers for obstruction relief.
• Anticoagulation: indicated for patients with atrial fibrillation or left atrial enlargement to prevent stroke (warfarin or direct oral anticoagulants).
• Sodium‑glucose co‑transporter‑2 (SGLT2) inhibitors: emerging evidence suggests benefit in improving cardiac output in HCM with heart failure (NEJM 2022).

Procedural Interventions

• Septal reduction therapy:
  • Surgical myectomy – removal of a portion of the hypertrophied septum; gold standard for severe obstruction.
  • Alcohol septal ablation (ASA) – percutaneous injection of ethanol into a septal branch to induce controlled infarction; less invasive but not suitable for all anatomies.
• Implantable cardioverter‑defibrillator (ICD): recommended for patients with:
  • Family history of SCD.
  • Documented NSVT or sustained ventricular tachycardia.
  • Maximum wall thickness ≥30 mm.
  • LGE >15 % of LV mass on CMR.
• Pacemaker implantation: indicated for patients with symptomatic bradycardia or advanced AV block.

Lifestyle and Supportive Measures

• Avoid high‑intensity competitive sports; moderate, low‑impact activities (e.g., walking, swimming) are generally safe.
• Maintain optimal blood pressure and weight to reduce afterload.
• Limit alcohol intake, as it can exacerbate arrhythmias.
• Educate family members about the hereditary nature and encourage cascade genetic screening.

Living with Quasi‑Septal Hypertrophic Cardiomyopathy

Long‑term management focuses on symptom monitoring, medication adherence, and regular follow‑up.

Daily Management Tips

• Medication schedule: take beta‑blockers or calcium channel blockers at the same time each day; keep a pill organizer.
• Monitor symptoms: maintain a diary of chest pain, shortness of breath, palpitations, or fainting episodes.
• Blood pressure and heart rate checks: aim for resting heart rate 50‑60 bpm (unless bradycardic) and systolic BP <130 mmHg.
• Physical activity: follow a graded exercise program prescribed by a cardiologist or cardiac rehab specialist; avoid sudden bursts of exertion.
• Vaccinations: stay up‑to‑date on influenza and COVID‑19 vaccines, as respiratory infections can precipitate decompensation.
• Stress management: anxiety can trigger arrhythmias; practice relaxation techniques (deep breathing, yoga, mindfulness).
• Travel considerations: carry a copy of your cardiac records and an emergency medication list; avoid exposure to extreme temperatures.

Follow‑up Schedule

Visit Type	Frequency	What’s Evaluated
Routine cardiology visit	Every 6‑12 months	Echocardiogram, symptom review, medication tolerance
Holter monitoring	Every 1‑2 years (or sooner if symptomatic)	Arrhythmia burden
CMR with LGE	Every 3‑5 years	Fibrosis progression, ICD need

Prevention

Because the primary driver is genetic, true primary prevention is limited, but several strategies can mitigate disease expression and complications.

• Family screening: first‑degree relatives should undergo baseline echocardiography and, when possible, genetic testing.
• Avoidance of intense competitive athletics: reduces mechanical stress on the septum.
• Control of blood pressure and lipid levels: lowers overall cardiac workload.
• Healthy lifestyle: balanced diet (Mediterranean style), regular moderate exercise, smoking cessation.
• Early detection of atrial fibrillation: routine rhythm checks to start anticoagulation promptly.

Complications

If left untreated or poorly managed, QSHCM can lead to serious outcomes.

• Progressive heart failure: due to diastolic dysfunction and, rarely, systolic decline.
• Left ventricular outflow‑tract obstruction: may become severe, causing refractory symptoms.
• Atrial fibrillation: prevalence up to 30 % in HCM cohorts; increases stroke risk.
• Ventricular arrhythmias: NSVT, sustained VT, or ventricular fibrillation → sudden cardiac death.
• Thromboembolic events: stroke or systemic embolism from atrial clot formation.
• End‑stage disease: rare transformation to a dilated, poorly contracting ventricle requiring heart transplantation.

When to Seek Emergency Care

---

Sources: Mayo Clinic, CDC, National Institutes of Health (NIH), World Health Organization (WHO), Cleveland Clinic, JACC, NEJM, American Heart Association (AHA) guidelines (2023). All links accessed July 2024.

```